Philip Howdle
@howdlep
Followers
1K
Following
9K
Media
212
Statuses
8K
UK Small Cap Trader of #IBAI (formerly #IQAI) and a lifelong supporter of @AVFCOfficial. Views my own, please DYOR.
Taunton
Joined October 2009
@grok summarise the significance of the Give Kids a Chance Act 2025 passing through the House of Representatives on 1 December 2025, in relation to Imaging Biometrics GaM phase I trial and their desire to be awarded two Rare Pediatric Disease Priority Review Vouchers (PRV).
1
0
0
#IBAI great news. Just remember, GE HealthCare could purchase Imaging Biometrics with small change, even at 50x the current price. Expansion Global Distribution Agreement with GE | Company Announcement | Investegate https://t.co/dw4DbLG0uR
investegate.co.uk
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies
0
0
0
#IBAI 👆Give Kids a Chance Act 2025 ( https://t.co/Vo1mYFfcss) passes unanimously through the House. Now just the Senate & Trumps signature. GaM Phase I FDA report & phase II update shortly. FDA drug approval could result in two Priority Review Vouchers worth $200m+ being granted
mccaul.house.gov
WASHINGTON – Today, the United States House of Representatives unanimously passed the Mikaela Naylon Give Kids A Chance Act, a landmark bill to accelerate pediatric cancer treatments and expand...
1
0
0
Grateful to Dr. Max Krucoff for today’s webinar! Delta T1 and FTB maps-along with interesting case studies-refine biopsy targeting, improve surgical planning! Look for the recording and an invite to our Jan. 6 webinar on QSM for Deep Brain Stimulation.
0
0
1
#IBAI 👀
Reminder: Live webinar this Wed.🗓️ November 19 | 12 PM CST Advanced Imaging Techniques For Biopsy Targeting and LITT in Recurrent Brain Tumors | Meeting-Join | Microsoft Teams
0
0
0
#IBAI great news & partly funded by the Musella Foundation for Brain Tumor Research & Information. IB FTB maps are FDA approved based on IB Neuro FDA approval Fractional Tumor Burden Mapping Enhances GBM Trial | Company Announcement | Investegate https://t.co/e7LwnrCezR
investegate.co.uk
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies
1
0
1
$IBAI Imaging Biometrics completes early-stage trial of new glioblastoma treatment https://t.co/rbxgILj7z6
@ImgBiometrics $5Y1 $IQAIF #IBAI #5Y1 #IQAIF
0
0
0
#IBAI should be a big volume day, as investors consider the End-of-Phase-1 meeting with the U.S. FDA & the Give Kids a Chance Act 2025, currently progressing through Congress, and its impact on the company being granted two Priority Review Vouchers, potentially worth $200m plus.
3
0
3
#IBAI a superb RNS. Congratulations to all the team. Tomorrow's volume could be very interesting indeed. IB Announces Completion of Phase 1 Trial of GaM | Company Announcement | Investegate
investegate.co.uk
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies
1
1
5
#IBAI and more 'real world data' from the Extended Access Program (EAP) could ensure far quicker FDA approval. We await the phase I completion RNS!!
The Phase 1 trial of oral gallium maltolate is closed to enrollment, but data is still being collected as patients continue treatment. The updated https://t.co/0boanoPiTt completion date reflects this — and it’s a good thing! More data = stronger insights, and a positive sign for
1
0
4
#IBAI IB Delta T1 maps are FDA approved, patent pending. FTB maps are FDA approved based on IB Neuro FDA approval.
Join us and learn how IB's exclusive FTB maps are being used in neurosurgery. IB Delta T1 & IB Neuro derived FTB maps provide automated, objective visualization of tumor burden by quantifying the fraction of active tumor within a lesion. ✅ No manual normalization ✅
0
0
3
#IBAI So the big question is, have @ImgBiometrics applied for Hub71 Cohort? Time will tell, but the benefits are clear. And how will the partnership with @vivanglobal develop, after they were successful with their Hub71 Cohort 17 application? Again, time will tell.
0
0
3